GuoLine Advisory’s Novo Nordisk NVO Stock Holding History

GuoLine Advisory’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$16.2M	Hold	426,700	–	–	1.39%	21
2026 Q2	$20.5M	Hold	426,700	–	–	1.91%	20
2026 Q1	$15.7M	Hold	426,700	–	–	1.64%	21
2025 Q4	$21.7M	Hold	426,700	–	–	2%	21
2025 Q3	$23.7M	Hold	426,700	–	–	2.36%	20
2025 Q2	$29.5M	Hold	426,700	–	–	3.12%	16
2025 Q1	$29.6M	Buy	426,700 +80,200	+23%	+$6.62M	3.14%	16
2024 Q4	$29.8M	Buy	346,500 +58,900	+20%	+$6.37M	3.08%	17
2024 Q3	$34.2M	Hold	287,600	–	–	3.49%	14
2024 Q2	$41.1M	Hold	287,600	–	–	4.38%	9
2024 Q1	$36.9M	Buy	287,600 +110,000	+62%	+$13.1M	4.5%	11
2023 Q4	$18.4M	Buy	+177,600	New	+$17.6M	2.91%	13

Other funds holding NVO

Everett Harris & Co Los Angeles, California $8.46B AUM 13.48% 1-Year Est. Return

Saratoga Research & Investment Management Saratoga, California $1.82B AUM 11.8% 1-Year Est. Return

Markel Group Glen Allen, Virginia $12.8B AUM 8.77% 1-Year Est. Return

Oppenheimer Asset Management New York $9.5B AUM 23.46% 1-Year Est. Return

Euro Pacific Asset Management Dorado, Puerto Rico $1.22B AUM 22.48% 1-Year Est. Return

Truist Financial Charlotte, North Carolina $84.4B AUM 20.16% 1-Year Est. Return

Nichols & Pratt Advisers Boston, Massachusetts $1.68B AUM 20.22% 1-Year Est. Return

Corda Investment Management Houston, Texas $1.52B AUM 30.53% 1-Year Est. Return

Philip James Wealth Mangement Milton, Georgia $906M AUM 30.39% 1-Year Est. Return

QV Investors Calgary, Alberta, Canada $1.36B AUM 20.86% 1-Year Est. Return

GuoLine Advisory's NVO Position: Q3 2026 in Review

GuoLine Advisory held its Novo Nordisk (NVO) position steady in Q3 2026 at 426,700 shares worth $16.2M. The position accounts for 1.39% of the portfolio, ranked #21.

GuoLine Advisory first reported a position in NVO in Q4 2023 and has held it in 12 quarters since. The position peaked at $41.1M in Q2 2024. 504 funds tracked by Wall St. Rank hold NVO as of Q3 2026.

GuoLine Advisory held 426,700 shares of Novo Nordisk worth $16.2M as of Q3 2026.
GuoLine Advisory left its Novo Nordisk share count unchanged in Q3 2026.
Novo Nordisk made up 1.39% of GuoLine Advisory's portfolio in Q3 2026, its #21 holding.
GuoLine Advisory first reported a position in Novo Nordisk in Q4 2023 and has held it in 12 quarters since.
GuoLine Advisory's Novo Nordisk position peaked at $41.1M in Q2 2024.
504 funds tracked by Wall St. Rank held Novo Nordisk as of Q3 2026.

Based on GuoLine Advisory's 13F filing for Q3 2026, filed 6 Oct 2026.